
    
      The aim of this phase 3 study was to evaluate the efficacy and safety of CKD-391 once daily
      for 8 weeks in patients with primary hypercholesterolemia. Furthermore, the extension study
      for additional 12 weeks is designed to confirm long term safety of CKD-391.
    
  